An Australian first


pathway future garden
Pembrolizumab (Keytruda) is the first medicine to have additional indications registered on the ARTG via the TGA’s provisional approval pathway “Pembrolizumab's indications now include the treatment of patients with metastatic colorectal carcinoma (bowel cancer) and other solid tumours with certain types of mutations (deficient mismatch repair),” the TGA says. It advised that the medicine’s Product

This content is restricted. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous ‘There is so much more rural community pharmacists could be doing.’
Next Is embedding non-dispensing pharmacists the 'wrong' approach?